samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > the solution to complex crispr modifications: droplet digital pcr
PUBLICATIONS
European Biopharmaceutical Review

The Solution to Complex CRISPR Modifications: Droplet Digital PCR

Development of the CRISPR-Cas system has unlocked new and improved opportunities in biological and genetic research, food production, and, increasingly, in the development of gene therapy and cell-based therapeutics. While the system was initially developed as a method to knock out target genes in functional studies, recent technical advances have extended this remit to selectively activate or repress target genes, purify specific regions of DNA, image DNA in live cells, and precisely edit DNA and RNA sequences.

However, as with all new developments, the full potential of this technology will only be reached if it is scientifically valuable, commercially transferable, cost-effective, and user friendly. While some applications of the conventional CRISPR-Cas system have achieved this, complex gene editing applications are still limited, including simultaneous multiple gene knock-out (KO), knock-in (KI) of longer length DNA fragments, and single-nucleotide modification (SNP) (1).

The chance of achieving complex CRISPR-Cas modifications can be enhanced by the addition of a Droplet Digital polymerase chain reaction (ddPCR). Like conventional PCR, ddPCR uses Taq polymerase to amplify target sequences using a validated primer, but with one key difference: the PCR mix is portioned into thousands of nanolitre-sized droplets. Such partitioning of the sample enables the screening of thousands of nucleic acid-containing droplets at once (see Figure 1) (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Karen McAulay began her career as a research scientist at the MRC Institute of Virology before moving to Edinburgh University, UK, to undertake her PhD thesis and develop a research portfolio investigating the immune response to Epstein–Barr virus (EBV) infection. In 2010, she moved to Glasgow University, UK, as a research fellow, with a focus on risk factors for EBV-associated disease. Currently, Karen is the Clinical Alliance Manager for REPROCELL (Biopta), with responsibility for maintaining the REPROCELL global tissue procurement network.

Zara Puckrin graduated last year with a first-class honors degree in Cell and Molecular Biology. During her studies, she was awarded a £2,000 vacation scholarship and the prize for the best academic poster in her graduate year. After undertaking part-time administrative work with REPROCELL (Biopta) in her final years of study, Zara is now working full time as Marketing Manager for the EMEA and US branches of the company.

Dr Robert Annand is a drug discovery scientist with more than 20 years’ experience in the field. After graduating with a PhD in Medicinal Chemistry and Biochemistry, he pursued a variety of research and management roles in the scientific and technical industry. Currently, Robert is Senior Technical Product Manager at REPROCELL (Stemgent).
spacer
Dr Karen McAulay
spacer
spacer
spacer
Zara Puckrin
spacer
spacer
spacer
Dr Robert Annand
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Shionogi Announces Publication of Two Studies in The Lancet Infectious Diseases Highlighting The Efficacy And Safety of Cefiderocol For The Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Shionogi announces publication of data from two of its clinical trials; APEKS-NP and CREDIBLE-CR in the journal The Lancet Infectious Diseases.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement